Antonio Regalado
Biotechnology Writer at MIT Technology Review
Progress in science depends on new techniques, new discoveries and new ideas, probably in that order - {Sydney Brenner}. I write about biotech @MIT @techreview
Articles
-
3 weeks ago |
technologyreview.es | Antonio Regalado
Brian Armstrong, el multimillonario CEO de la plataforma de criptomonedas Coinbase, dice estar dispuesto a financiar una empresa estadounidense dedicada a la edición genética de embriones humanos. Si sigue adelante, sería la primera gran inversión comercial en una de las ideas más delicadas de la medicina.
-
3 weeks ago |
technologyreview.com | Antonio Regalado
Brian Armstrong, the billionaire CEO of the cryptocurrency exchange Coinbase, says he’s ready to fund a US startup focused on gene-editing human embryos. If he goes forward, it would be the first major commercial investment in one of medicine’s most fraught ideas. In a post on X June 2, Armstrong announced he was looking for gene-editing scientists and bioinformatics specialists to form a founding team for an “embryo editing” effort targeting an unmet medical need, such as a genetic disease.
-
3 weeks ago |
mittechreview.com.br | Antonio Regalado
Os médicos dizem que desenvolveram uma terapia personalizada de edição de genes em menos de sete meses e o usaram para tratar um bebê com uma condição metabólica fatal. A tentativa acelerada de corrigir o DNA da criança marca a primeira vez que a edição genômica foi adaptada para tratar um único indivíduo, de acordo com um relatório publicado no New England Journal of Medicine.
-
1 month ago |
technologyreview.com | Caiwei Chen |Antonio Regalado
Since the Chinese biophysicist He Jiankui was released from prison in 2022, he has sought to make a scientific comeback and to repair his reputation after a three-year incarceration for illegally creating the world’s first gene-edited children. While he has bounced between cities, jobs, and meetings with investors, one area of visible success on his come-back trail has been his X.com account, @Jiankui_He, which has become his main way of spreading his ideas to the world.
-
1 month ago |
technologyreview.es | Antonio Regalado
Las patentes CRISPR vuelven a estar en juego. Este lunes Tribunal de Apelación del Circuito Federal de EE UU declaró que las científicas Jennifer Doudna y Emmanuelle Charpentier tendrán otra oportunidad de demostrar que merecen ser las propietarias de las patentes clave de lo que muchos consideran el invento biotecnológico más importante del siglo XXI.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 27K
- Tweets
- 25K
- DMs Open
- Yes
COI alert: FDA commissioner giving self right to expedite drug approvals. Amounts to handouts by a political appointee, according to STAT. These are worth a lot of money and therefore could invite new forms of favoritism, graft and influence selling.
There are a LOT of problems with the FDA Commissioner's National Priority Vouchers. First that they're given out by the commissioner. But also: faster drug approvals are good, but these would be faster than any drug approvals ever. Big promises like this should be approached
Kennedy says HHS will follow gold standard science on vaccines, but recent actions suggest otherwise. “I could not be party to legitimizing this new committee,” she said. “I just no longer had confidence that the data...was going to be used objectively.” https://t.co/2CXfdKEPK8
The latest prediction by Nostradamus, i mean by Ray Kurzweil, in Popular Mechanics. Love this soothsaying headline treatment. Have set a reminder for my older (younger?) self to check in on this prediction in 4 years. https://t.co/I9jOJ1vZgB
